Logo image of COEP

COEPTIS THERAPEUTICS HOLDING (COEP) Stock Overview

NASDAQ:COEP - US19207A2078 - Common Stock

13.325 USD
+0.66 (+5.25%)
Last: 8/29/2025, 8:14:07 PM

COEP Key Statistics, Chart & Performance

Key Statistics
52 Week High14.7
52 Week Low2.31
Market Cap64.23M
Shares4.82M
Float4.17M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-17.58
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO12-17 2020-12-17
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


COEP short term performance overview.The bars show the price performance of COEP in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30 40

COEP long term performance overview.The bars show the price performance of COEP in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 50 100 150 200

The current stock price of COEP is 13.325 USD. In the past month the price increased by 24.3%. In the past year, price increased by 226.11%.

COEPTIS THERAPEUTICS HOLDING / COEP Daily stock chart

COEP Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.87 371.68B
AMGN AMGEN INC 13.19 154.89B
GILD GILEAD SCIENCES INC 14.6 140.17B
VRTX VERTEX PHARMACEUTICALS INC 23.08 100.25B
REGN REGENERON PHARMACEUTICALS 12.72 61.55B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.53B
ARGX ARGENX SE - ADR 76.83 43.59B
ONC BEONE MEDICINES LTD-ADR 6.16 36.38B
INSM INSMED INC N/A 28.77B
BNTX BIONTECH SE-ADR N/A 24.04B
NTRA NATERA INC N/A 23.09B
BIIB BIOGEN INC 8.26 19.38B

About COEP

Company Profile

COEP logo image Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company, which engages in developing innovative cell therapy platforms for cancer that can disrupt conventional treatment paradigms and improve patient outcomes. The company is headquartered in Wexford, Pennsylvania and currently employs 5 full-time employees. The company went IPO on 2020-12-17. The firm is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.

Company Info

COEPTIS THERAPEUTICS HOLDING

105 Bradford Road, Suite 420

Wexford PENNSYLVANIA US

Employees: 6

COEP Company Website

COEP Investor Relations

Phone: 17249346467

COEPTIS THERAPEUTICS HOLDING / COEP FAQ

What is the stock price of COEPTIS THERAPEUTICS HOLDING today?

The current stock price of COEP is 13.325 USD. The price increased by 5.25% in the last trading session.


What is the ticker symbol for COEPTIS THERAPEUTICS HOLDING stock?

The exchange symbol of COEPTIS THERAPEUTICS HOLDING is COEP and it is listed on the Nasdaq exchange.


On which exchange is COEP stock listed?

COEP stock is listed on the Nasdaq exchange.


What is COEPTIS THERAPEUTICS HOLDING worth?

COEPTIS THERAPEUTICS HOLDING (COEP) has a market capitalization of 64.23M USD. This makes COEP a Micro Cap stock.


How many employees does COEPTIS THERAPEUTICS HOLDING have?

COEPTIS THERAPEUTICS HOLDING (COEP) currently has 6 employees.


What are the support and resistance levels for COEPTIS THERAPEUTICS HOLDING (COEP) stock?

COEPTIS THERAPEUTICS HOLDING (COEP) has a support level at 12.65 and a resistance level at 13.97. Check the full technical report for a detailed analysis of COEP support and resistance levels.


Is COEPTIS THERAPEUTICS HOLDING (COEP) expected to grow?

The Revenue of COEPTIS THERAPEUTICS HOLDING (COEP) is expected to decline by -100% in the next year. Check the estimates tab for more information on the COEP EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy COEPTIS THERAPEUTICS HOLDING (COEP) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does COEPTIS THERAPEUTICS HOLDING (COEP) stock pay dividends?

COEP does not pay a dividend.


What is the Price/Earnings (PE) ratio of COEPTIS THERAPEUTICS HOLDING (COEP)?

COEPTIS THERAPEUTICS HOLDING (COEP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-17.58).


What is the Short Interest ratio of COEPTIS THERAPEUTICS HOLDING (COEP) stock?

The outstanding short interest for COEPTIS THERAPEUTICS HOLDING (COEP) is 2.67% of its float. Check the ownership tab for more information on the COEP short interest.


COEP Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to COEP. When comparing the yearly performance of all stocks, COEP is one of the better performing stocks in the market, outperforming 97.78% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

COEP Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to COEP. COEP has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

COEP Financial Highlights

Over the last trailing twelve months COEP reported a non-GAAP Earnings per Share(EPS) of -17.58. The EPS increased by 63.79% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -260.16%
ROE -486.73%
Debt/Equity 0.03
Chartmill High Growth Momentum
EPS Q2Q%95.75%
Sales Q2Q%N/A
EPS 1Y (TTM)63.79%
Revenue 1Y (TTM)N/A

COEP Forecast & Estimates

For the next year, analysts expect an EPS growth of 98.47% and a revenue growth -100% for COEP


Analysts
Analysts43.33
Price TargetN/A
EPS Next Y98.47%
Revenue Next Year-100%

COEP Ownership

Ownership
Inst Owners4.33%
Ins Owners16.94%
Short Float %2.67%
Short Ratio1.59